5 USD
+0.01 (+0.2%)
5 USD
0 (0%)
TSVT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. The financial health of TSVT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, TSVT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year TSVT has reported negative net income.
- TSVT had a negative operating cash flow in the past year.
- In the past 5 years TSVT always reported negative net income.
- TSVT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- TSVT has a Return On Assets of -11.94%. This is amongst the best in the industry. TSVT outperforms 83.81% of its industry peers.
- Looking at the Return On Equity, with a value of -27.16%, TSVT is in the better half of the industry, outperforming 79.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.94% | ||
| ROE | -27.16% | ||
| ROIC | N/A |
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of TSVT (52.43%) is better than 77.22% of its industry peers.
- In the last couple of years the Gross Margin of TSVT has declined.
- The Profit Margin and Operating Margin are not available for TSVT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
2. Health
2.1 Basic Checks
- TSVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- TSVT has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, TSVT has more shares outstanding
- TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- TSVT has an Altman-Z score of -1.30. This is a bad value and indicates that TSVT is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -1.30, TSVT is in line with its industry, outperforming 59.07% of the companies in the same industry.
- TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.3 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
- TSVT has a Current Ratio of 4.67. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
- TSVT has a Current ratio (4.67) which is comparable to the rest of the industry.
- TSVT has a Quick Ratio of 4.67. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 4.67, TSVT is in line with its industry, outperforming 53.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.67 | ||
| Quick Ratio | 4.67 |
3. Growth
3.1 Past
- TSVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.14%, which is quite impressive.
- TSVT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.28%.
- Measured over the past years, TSVT shows a decrease in Revenue. The Revenue has been decreasing by -3.09% on average per year.
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%
3.2 Future
- TSVT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.56% yearly.
- Based on estimates for the next years, TSVT will show a quite strong growth in Revenue. The Revenue will grow by 12.75% on average per year.
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TSVT. In the last year negative earnings were reported.
- Also next year TSVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TSVT's earnings are expected to grow with 30.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.7%
EPS Next 3Y30.96%
5. Dividend
5.1 Amount
- TSVT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2SEVENTY BIO INC / TSVT FAQ
What is the ChartMill fundamental rating of 2SEVENTY BIO INC (TSVT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TSVT.
What is the valuation status for TSVT stock?
ChartMill assigns a valuation rating of 1 / 10 to 2SEVENTY BIO INC (TSVT). This can be considered as Overvalued.
How profitable is 2SEVENTY BIO INC (TSVT) stock?
2SEVENTY BIO INC (TSVT) has a profitability rating of 2 / 10.
What is the expected EPS growth for 2SEVENTY BIO INC (TSVT) stock?
The Earnings per Share (EPS) of 2SEVENTY BIO INC (TSVT) is expected to grow by 58.41% in the next year.